Natural Alternatives International (NASDAQ:NAII – Get Free Report) and Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.
Analyst Recommendations
This is a summary of current ratings and target prices for Natural Alternatives International and Zevra Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Natural Alternatives International | 1 | 0 | 0 | 0 | 1.00 |
| Zevra Therapeutics | 1 | 1 | 6 | 0 | 2.63 |
Zevra Therapeutics has a consensus target price of $24.00, suggesting a potential upside of 126.20%. Given Zevra Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Zevra Therapeutics is more favorable than Natural Alternatives International.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Natural Alternatives International | $129.86 million | 0.13 | -$13.57 million | ($2.27) | -1.20 |
| Zevra Therapeutics | $23.61 million | 25.22 | -$105.51 million | ($0.21) | -50.52 |
Natural Alternatives International has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Natural Alternatives International, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
32.4% of Natural Alternatives International shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 20.9% of Natural Alternatives International shares are owned by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Natural Alternatives International has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.
Profitability
This table compares Natural Alternatives International and Zevra Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Natural Alternatives International | -10.45% | -9.69% | -4.73% |
| Zevra Therapeutics | 4.33% | -112.40% | -37.67% |
Summary
Zevra Therapeutics beats Natural Alternatives International on 8 of the 14 factors compared between the two stocks.
About Natural Alternatives International
Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.
About Zevra Therapeutics
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.
Receive News & Ratings for Natural Alternatives International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natural Alternatives International and related companies with MarketBeat.com's FREE daily email newsletter.
